Boston Scientific (NYSE:BSX) Price Target Cut to $48.00 by Analysts at Citigroup

Boston Scientific (NYSE:BSX) had its price objective lowered by analysts at Citigroup from $50.00 to $48.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical equipment provider’s stock. Citigroup’s price objective would suggest a potential upside of 12.93% from the company’s current price.

A number of other equities research analysts also recently weighed in on BSX. Robert W. Baird set a $56.00 price objective on Boston Scientific in a report on Thursday, July 30th. Royal Bank Of Canada lowered their price target on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, July 30th. BTIG Research cut their price objective on Boston Scientific from $60.00 to $56.00 and set a “buy” rating for the company in a report on Wednesday, September 9th. Leerink Partners set a $60.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Finally, Oppenheimer cut their price target on shares of Boston Scientific from $85.00 to $65.00 and set an “outperform” rating for the company in a report on Monday, September 21st. Twenty-three research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $67.88.

Boston Scientific Stock Performance

BSX stock traded down $0.10 during midday trading on Monday, hitting $42.50. The stock had a trading volume of 9,294,325 shares, compared to its average volume of 18,722,592. Boston Scientific has a 52 week low of $41.94 and a 52 week high of $105.65. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The stock has a 50-day simple moving average of $46.95 and a 200 day simple moving average of $51.51. The firm has a market capitalization of $61.60 billion, a price-to-earnings ratio of 17.20, a P/E/G ratio of 1.02 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts anticipate that Boston Scientific will post 3.25 earnings per share for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director David Habiger purchased 2,100 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward Ludwig purchased 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The shares were bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 194,522 shares of company stock valued at $9,385,210 over the last ninety days. 0.34% of the stock is owned by insiders.

Institutional Trading of Boston Scientific

A number of hedge funds and other institutional investors have recently modified their holdings of BSX. Neville Rodie & Shaw Inc. raised its position in shares of Boston Scientific by 35.2% during the third quarter. Neville Rodie & Shaw Inc. now owns 24,295 shares of the medical equipment provider’s stock worth $1,060,000 after acquiring an additional 6,325 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in Boston Scientific by 50.9% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 6,549 shares of the medical equipment provider’s stock valued at $286,000 after acquiring an additional 2,209 shares during the last quarter. QRG Capital Management Inc. increased its position in Boston Scientific by 129.4% in the second quarter. QRG Capital Management Inc. now owns 375,620 shares of the medical equipment provider’s stock worth $16,031,000 after purchasing an additional 211,855 shares during the period. Andra AP fonden increased its position in Boston Scientific by 13.9% in the second quarter. Andra AP fonden now owns 193,622 shares of the medical equipment provider’s stock worth $8,264,000 after purchasing an additional 23,694 shares during the period. Finally, SkyView Investment Advisors LLC bought a new stake in Boston Scientific during the 2nd quarter worth about $107,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.